ESMO 2022

Consolidating data from prospective studies

Simple and cheap surgical technique may impact survival in early breast cancer

Endocrine response in eBC

Reduction of peripheral neuropathy with taxane therapy

Long-term data on dose density therapy in chemotherapy

Dose-dense therapy is beneficial for all patients

DD is the champion!

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

Dose-dense standard of care is the optimal care

My highlights of ESMO22

Roadmap for the adjuvant setting

Immuntherapy only for low risk patients?

Dose dense is better

QoL and longterm toxicity

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

Schéma dose-dense bénéfique pour toutes les patientes

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

I miei punti salienti di ESMO22

Il vincitore e’ il dose dense!!

Datele trialurilor se consolideata

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

Tailoring Adjuvant Therapy

How to deal with the negative SERD data?

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

Status update - adjuvant IO. Are TILs prognostic?

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

Unmeet needs and my wishes for 2022!

CDK4/6i could be an option for selected ER+/HER2+ disease

ADC after ADC - is there any orientation?

More therapy options for patients with HR+, HER2+ disease

The third in the bunch

VEX has no place in chemotherapy of metastatic breast cancer

Interim analysis shows promising data on Abema in the 1st Line

New treatment option for heavily pre-treated patients with ER+ MBC

Survival benefit from SG in mBC

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

Update on biomarkers on ADCs of the DAISY trial

OS not significant, but re-assuring new data

Survival benefit in endocrine sensitive patients

My highlights of ESMO22

TROPiCS-02 highlights

Discontinued development

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Sacituzumab govitecan for everybody!

Another option for heavily pre-treated HR+ advanced breast cancer patients

Negative and yet positive?!

SG is a novel treatment option for HR+/HER2- disease

Exciting data, but Phase 3 studies are needed

HER2+ and still without chemotherapy

Survie globale pas encore significative statistiquement mais données rassurantes

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

Sacituzumab Govitecan: Un farmaco per tutte?

Nouvelles données des analyses expolratoires dans l’étude DAISY

I miei punti salienti di ESMO22

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

TROPiCS-02 highlights

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

Sopravvivenza globale nello studio MONARCH3

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

ADAURA Update - preventing relapse or just delaying it?

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Osimertinib stays standard adjuvant

Concurrent preoperative IO/CRT in early lung cancer

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Pollution and lung cancer - one mechanism revealed

Long term follow-up of ADAURA trial

Is OS really needed?

INCREASE - to good to be true?

Neoadjuvant strategies for PD-L1 < 1 %

ADAURA revisited

Osimertinib - curing or delaying relapse?

Window for treatment selection

Osimertinib bleibt Standard adjuvant

ADAURA revisited

Pollution et cancer du poumon - un mécanisme mis en évidence

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

Osimertinib: una cura o ritarda la ripresa di malattia?

Langzeitdaten ADAURA

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Eine Plattform für "take the winner"-Strategie

DFS matters!

Important data on borderline resectable patients

Can IO be discontinued?

Sotorasib vs. Docetaxel in mKRAS G12C

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

A new step in treatment of KRAS G12C mutant NSCLC

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

New therapy combination after progression on 1L osimertinib

Liquid biopsy monitoring in treatment decisions

Pneumonitis and T-DXd

DESTINY-Lung02 - better than the original?

Is shorter immunotherapy equally effective and less physically demanding?

Real-world data on Atezolizumab

Induction chemoimmunotherapy in borderline resectability?

Cemiplimab beyond progression?

Preview on lung cancer highlights

5 years of chemoimmunotherapy: solid grounded

Question about timing and duration of immunotherapy still unanswered

New immunotherapy options for pts. ineligible to 1st line platinum therapy

The journey at KRAS G12C continues

Immunotherapy in unfit population? Perhaps...

Sotorasib - a new standard of care?

Sotorasib: sweet and sour results

Chemoimmunotherapy - improvement of survival after 5 years

Can we finally treat poor prognostic patients with immunotherapy?

5-year update on 1st line chemoimmunotherapy

Emerging IO mono options in the first line

One more brick in the KRAS G12C wall

Poseidon and STK11/KEAP

Atezolizumab better than vinorelbin in reduced performance status

5-year data on survival under immunotherapy

HER2 - the next actionable mutation in lung cancer?

If you don't look, vou don't find - once you found it, you'll treat it!

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Les études incontournables à l’ESMO 2022

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

5-Jahresüberleben mit Immuntherapie

Données de vie réelle avec l’atezolizumab

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

IO-IO neoadjuvant bei PD-L1 neg.

Poseidon und STK11/KEAP

Cemiplimab beyond progression?

Sotorasib vs. Docetaxel bei mKRAS G12C

Pneumonitis und T-DXd

Kann IO pausiert werden?

Atezo besser als Vino bei PS2-3

Neue Option der IO-Therapie in der Erstlinie

Liquid Biopsy Monitoring zur Therapiesteuerung

Die Reise bei KRAS G12C geht weiter

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

5 Jahre Chemo-Immuntherapie: starker Effekt

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

Immunoterapia nella popolazione non fit: forse

Neue Therapiekombination in der Resistenz nach Osimertinib

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

Resultados Agridulces de Sotorasib

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Chimio-immunothérapie - amélioration de la survie après 5 ans

Un mattone in piu' nel muro del KRAS G12C

Heterogenity in the genetic landscape - little progress in molecular alterations

New strategies in immunotherapy

Novel data and long-term efficacy of chemo-IO in mNSCLC

A positive study! With a question mark?

Place of triplet therapy

Two negative studies question adjuvant approach in RCC

Adjuvant Immuntherapy in kidney cancer

More questions being raised

Immune-based peri-operative treatment in RCC: What went wrong?

News in terms of adjuvant

No value of IPI/Nivo in the adjuvant setting.

Brief highlights about RCC & urothelial cancer from ESMO22

New combo - triplet therapy for kidney cancer

Exciting data for high-risk patients: is this the start of a new era?

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

Inmunoterapia adyuvante en el cancer renales

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Terapia triple para cancer renales

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Immunomodulation in combination with checkpointinhibiton

Therapy combinations in RCC - what is the role of triplet therapy?

Shedding light on TKI/Checkpointinhibitor combinations

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

EV + pembrolizumab in cisplatin-ineligible patients

EV + Pembro with excellent response rates

Brief highlights about RCC & urothelial cancer from ESMO22

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

Promising data, but beware of toxicity

Genetic testing before PARP therapy is useful

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Cabazitaxel better tolerated in elderly men

IO + PARP without benefit in the allcomer situation

QoL data from ARASENS triplet therapy study mHRPC

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

Radicals - ADT & Radiotherapy

PSA at 8-months as a biomarker

Triplet therapy with darolutamide in prostate cancer

Combination of olaparib leads to promising results

Further evaluation of PSA correlates

Length of hormone therapy after radiation

ADT + ENZA better choice than monotherapy

In older vulnerable - less is more

Update on the PROpel study

ADCs - a possible therapeutic approach

Optimizing cabazitaxel chemotherapy

Biomarker data for better patients selection

Livskvalitetsuppföljning i ARASENS studien

PSA efter 8 månader i PEACE-1 studien som biomarkör

Uppdatering i PROpel studien

Practice changing data - only for older and more vulnerable patients?

Positive results, but testing not that simple

PSA response after triplet therapy: What is the impact in clinical practice?

Which men benefit from adding ADT?

Modern Imaging is the new standard

Intimate partner violence in cancer patients

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy

Novel approach von Biontech towards Cancer – game changing potential?!

Addition of CPI to Radiochemotherapy in LA-HNSCC?

TILs - Fashion is the eternal return of the old

New group of substances for rare diseases